ICS + LABA inhaler (once-daily)
Fluticasone with vilanterol
Brand names: Relvar Ellipta
Adult dose
Dose: 1 inhalation OD; 92/22 (asthma & COPD) or 184/22 (asthma)
Route: Inhaled
Frequency: OD
Clinical pearls
- Once-daily ICS/LABA — adherence advantage
- Not a reliever
Contraindications
- Severe milk-protein allergy
Side effects
- Pneumonia (COPD)
- Oral candidiasis
- Hoarseness
- Headache
- Tremor
Interactions
- β-blockers
- Strong CYP3A4 inhibitors
- QT-prolonging drugs
Reference: BNF; NICE NG115/NG80; https://bnf.nice.org.uk/drugs/fluticasone-with-vilanterol/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Insulin TDD Estimator · Diabetes
- Harris-Benedict Equation — Resting Energy Expenditure · Nutrition
- Lawton IADL Scale — Instrumental Activities of Daily Living · Function
- Katz Index of Independence in Activities of Daily Living · Function
- Barthel Index of Activities of Daily Living · Functional Outcome
- Katz Index of Independence in ADL · Functional Assessment
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024